The present invention provides the use of an inhibitor of glycolipid biosynthesis in the manufacture of a medicament for the treatment of a glycolipid-mediated autoimmune disease.
SUBSTRATE REDUCTION THERAPY
申请人:Platt Mary Frances
公开号:US20100204162A1
公开(公告)日:2010-08-12
The present invention provides a compound which is an inhibitor of sphingolipid biosynthesis for use in the treatment of a disease which has a secondary Niemann-Pick type C disease like cellular phenotype.